WO2006101845A3 - Synthesis and purification of pteroic acid and conjugates thereof - Google Patents

Synthesis and purification of pteroic acid and conjugates thereof Download PDF

Info

Publication number
WO2006101845A3
WO2006101845A3 PCT/US2006/009153 US2006009153W WO2006101845A3 WO 2006101845 A3 WO2006101845 A3 WO 2006101845A3 US 2006009153 W US2006009153 W US 2006009153W WO 2006101845 A3 WO2006101845 A3 WO 2006101845A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
acid
pteroic acid
purification
synthesis
Prior art date
Application number
PCT/US2006/009153
Other languages
French (fr)
Other versions
WO2006101845A2 (en
Inventor
Le-Cun Xu
Iontcho Radoslavov Vlahov
Christopher Paul Leamon
Hari Krishna Santhapuram
Chunhong Li
Original Assignee
Endocyte Inc
Le-Cun Xu
Iontcho Radoslavov Vlahov
Christopher Paul Leamon
Hari Krishna Santhapuram
Chunhong Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc, Le-Cun Xu, Iontcho Radoslavov Vlahov, Christopher Paul Leamon, Hari Krishna Santhapuram, Chunhong Li filed Critical Endocyte Inc
Priority to CN2006800162870A priority Critical patent/CN101175757B/en
Priority to US11/908,695 priority patent/US8044200B2/en
Priority to EP06738235.8A priority patent/EP1863816B1/en
Priority to JP2008501969A priority patent/JP5289935B2/en
Publication of WO2006101845A2 publication Critical patent/WO2006101845A2/en
Publication of WO2006101845A3 publication Critical patent/WO2006101845A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods for purifying pteroic acid, analogs of pteroic acid, and derivatives of pteroic acid are described. Methods for synthesizing and purifying conjugates of vitamins, including FITC conjugates of folic acid, folic acid analogs, and derivatives of folic acid and folic acid analogs are also described. Purified forms of pteroic acid, derivatives and analogs of pteroic acid, and conjugates thereof are also described.
PCT/US2006/009153 2005-03-16 2006-03-14 Synthesis and purification of pteroic acid and conjugates thereof WO2006101845A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN2006800162870A CN101175757B (en) 2005-03-16 2006-03-14 Synthesis and purification of pteroic acid and conjugates thereof
US11/908,695 US8044200B2 (en) 2005-03-16 2006-03-14 Synthesis and purification of pteroic acid and conjugates thereof
EP06738235.8A EP1863816B1 (en) 2005-03-16 2006-03-14 Synthesis and purification of pteroic acid and conjugates thereof
JP2008501969A JP5289935B2 (en) 2005-03-16 2006-03-14 Synthesis and purification of pteroic acid and its conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66227705P 2005-03-16 2005-03-16
US60/662,277 2005-03-16

Publications (2)

Publication Number Publication Date
WO2006101845A2 WO2006101845A2 (en) 2006-09-28
WO2006101845A3 true WO2006101845A3 (en) 2007-03-29

Family

ID=36699050

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/009153 WO2006101845A2 (en) 2005-03-16 2006-03-14 Synthesis and purification of pteroic acid and conjugates thereof

Country Status (5)

Country Link
US (1) US8044200B2 (en)
EP (1) EP1863816B1 (en)
JP (1) JP5289935B2 (en)
CN (1) CN101175757B (en)
WO (1) WO2006101845A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8685752B2 (en) 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
US8808998B2 (en) 2003-05-30 2014-08-19 Purdue Research Foundation Diagnostic method for atherosclerosis
US8858914B2 (en) 2002-02-07 2014-10-14 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8865128B2 (en) 2002-02-07 2014-10-21 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8916167B2 (en) 2001-05-02 2014-12-23 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8961926B2 (en) 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9180215B2 (en) 2007-02-07 2015-11-10 Purdue Research Foundation Positron emission tomography imaging method
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9550734B2 (en) 2004-07-23 2017-01-24 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085908A1 (en) 2001-04-24 2002-10-31 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
WO2004069159A2 (en) * 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
JP5289935B2 (en) 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド Synthesis and purification of pteroic acid and its conjugates
JP5175723B2 (en) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション Preparation of compositions for treating monocyte-mediated diseases
JP5475992B2 (en) * 2005-08-19 2014-04-16 エンドサイト，インコーポレイテッド Multidrug ligand conjugate
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN107573347A (en) 2007-04-11 2018-01-12 默克和西伊公司 18The folic acid of F marks
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP2349274A4 (en) 2008-09-17 2014-12-17 Endocyte Inc Folate receptor binding conjugates of antifolates
JP2013501224A (en) * 2009-07-31 2013-01-10 エンドサイト，インク． Diagnosis and treatment targeting folic acid
EP2476414B1 (en) * 2009-09-07 2015-03-04 NIPRO Patch Co., Ltd. Transdermally absorbable preparation
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
KR20150070318A (en) 2012-10-16 2015-06-24 엔도사이트, 인코포레이티드 Drug delivery conjugates containing unnatural amino acids and methods for using
US9333270B2 (en) * 2013-03-15 2016-05-10 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
US11162937B2 (en) 2013-11-19 2021-11-02 Purdue Research Foundation Patient selection method for inflammation
US10239891B2 (en) * 2017-05-15 2019-03-26 Indicator Systems International, Inc. Compositions to detect remnant cancer cells
US20180036312A1 (en) * 2016-08-02 2018-02-08 ISI Life Sciences Inc. Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells
WO2018026965A1 (en) 2016-08-02 2018-02-08 Isi Life Sciences, Inc. Compositions and methods for detecting cancer cells in a tissue sample
CN106420394B (en) * 2016-10-21 2019-05-10 江南大学 A method of enhancing folic acid photostability
US10753942B2 (en) 2017-05-15 2020-08-25 Indicator Systems International, Inc. Methods to detect remnant cancer cells
CN109734717B (en) * 2019-01-24 2022-03-22 苏州华健瑞达医药技术有限公司 Novel crystal form of pteroic acid and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337339A (en) * 1979-04-30 1982-06-29 Baker Instruments Corp. Process for preparation of folic acid derivatives
US20030162234A1 (en) * 2002-02-07 2003-08-28 Jallad Karim N. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2515483A (en) * 1946-08-10 1950-07-18 Merck & Co Inc Diacylated pteroic acid and process for preparing same
US2816110A (en) 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US3392173A (en) * 1964-03-09 1968-07-09 Lilly Co Eli Novel acyl derivatives of desacetyl-vincaleukoblastine and processes for their preparation
US3387001A (en) * 1964-10-19 1968-06-04 Lilly Co Eli Novel aminoacyl esters of desacetyl vincaleukoblastine
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4166810A (en) * 1978-04-20 1979-09-04 Eli Lilly And Company Derivatives of 4-desacetyl VLB C-3 carboxyhydrazide
US4639456A (en) 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US5140104A (en) * 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
DE3376114D1 (en) 1982-12-07 1988-05-05 Kyowa Hakko Kogyo Kk Mitomycin analogues
US4866180A (en) * 1984-02-24 1989-09-12 Bristol-Myers Company Amino disulfide thiol exchange products
JPS60255789A (en) * 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd Mitomycin derivative, its preparation, and antitumor agent
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
IL82579A0 (en) 1986-05-27 1987-11-30 Lilly Co Eli Immunoglobulin conjugates
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
WO1988001622A1 (en) 1986-08-29 1988-03-10 Kyowa Hakko Kogyo Kabusiki Kaisha Mitomycin derivatives
US5094849A (en) * 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5006652A (en) 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5998603A (en) 1994-09-29 1999-12-07 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analogs, and oligomers thereof
WO1992003569A1 (en) * 1990-08-29 1992-03-05 Centre Hospitalier Regional De Nantes Protein polyligands joined to a stable protein core
US5130307A (en) * 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5169851A (en) 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5159079A (en) * 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
DE69430060T2 (en) * 1993-04-23 2002-11-07 Abbott Lab RAPAMYCINE ANTIBODIES WITH OPEN RING
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
IL112873A (en) * 1994-03-08 2005-03-20 Wyeth Corp Rapamycin-fkbp12 binding proteins, their isolation and their use
US6171859B1 (en) * 1994-03-30 2001-01-09 Mitokor Method of targeting conjugate molecules to mitochondria
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6030941A (en) * 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
EP0954340B1 (en) * 1996-05-03 2007-06-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer
DE19621133A1 (en) * 1996-05-24 1997-11-27 Boehringer Mannheim Gmbh Determination method with oligomerized receptors
CA2265476A1 (en) 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
US6177404B1 (en) * 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
WO1999020626A1 (en) 1997-10-17 1999-04-29 Purdue Research Foundation Folic acid derivatives
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6093382A (en) * 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
CN100512879C (en) * 1999-04-23 2009-07-15 阿尔萨公司 Conjugate having cleavable linkage for use in liposome
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
AUPQ071299A0 (en) 1999-06-02 1999-06-24 Access Pharmaceuticals Australia Pty Limited Vitamin directed dual targeting therapy
KR20020059618A (en) * 1999-10-15 2002-07-13 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Cobalamin conjugates useful as imaging agents and as antitumor agents
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
CN1441676B (en) * 2000-03-31 2012-08-22 普渡研究基金会 Method of treatment using ligand-immunogen conjugates
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
ATE278421T1 (en) * 2000-08-11 2004-10-15 Wyeth Corp METHOD FOR TREATING ESTROGEN RECEPTOR POSITIVE CARCINOMA
WO2002024706A2 (en) * 2000-09-19 2002-03-28 Wyeth Water soluble rapamycin esters
US6399625B1 (en) * 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) * 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) * 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
BR0115715A (en) 2000-11-28 2004-02-03 Wyeth Corp Nucleic acid and polypeptide expression analysis useful in prostate cancer diagnosis and treatment
AR036993A1 (en) * 2001-04-02 2004-10-20 Wyeth Corp USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
CA2442066C (en) * 2001-04-02 2005-11-01 Wyeth Pd-1, a receptor for b7-4, and uses therefor
WO2002085908A1 (en) * 2001-04-24 2002-10-31 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
US20040018203A1 (en) * 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CA2455311A1 (en) * 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
DE60206512T2 (en) * 2001-08-22 2006-06-22 Wyeth RAPAMYCIN 29-ENOLE
CA2461877A1 (en) * 2001-09-28 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
GR1004163B (en) * 2001-11-01 2003-02-21 Polycarbocyclic derivatives for modification of resist, optical and etch resistance properties
US7000695B2 (en) * 2002-05-02 2006-02-21 Halliburton Energy Services, Inc. Expanding wellbore junction
ES2438008T3 (en) * 2002-05-06 2014-01-15 Endocyte, Inc. Vitamin-directed imaging agents
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
KR20040106547A (en) * 2002-05-15 2004-12-17 엔도사이트, 인코포레이티드 Vitamin-mitomycin conjugates
AU2003266233A1 (en) * 2002-07-09 2004-01-23 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Novel tubulysin analogues
US7122361B2 (en) 2002-10-10 2006-10-17 Wyeth Compositions employing a novel human kinase
BR0316476A (en) * 2002-11-21 2005-10-11 Wyeth Corp Composition and process for treating lupus nephritis
DE10254439A1 (en) * 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysins, manufacturing processes and tubulysin agents
WO2004069159A2 (en) * 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
AR042938A1 (en) * 2003-02-06 2005-07-06 Wyeth Corp USE OF CCI-779 IN THE TREATMENT OF HEPATIC FIBROSIS
EP2660322A3 (en) * 2003-04-17 2013-11-13 Alnylam Pharmaceuticals Inc. Modified iRNA agents
WO2004101803A2 (en) * 2003-05-12 2004-11-25 Wyeth Holdings Corporation Process for producing anticancer agent ll-d45042
AU2004259669A1 (en) * 2003-07-16 2005-02-03 Wyeth CCI-779 Isomer C
CN1829722B (en) 2003-08-07 2010-10-27 惠氏公司 Regioselective synthesis of CCI-779
WO2006012527A1 (en) * 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
JP5192234B2 (en) * 2004-08-10 2013-05-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド Chemically modified oligonucleotide
JP5289935B2 (en) 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド Synthesis and purification of pteroic acid and its conjugates
AU2006230219A1 (en) 2005-03-30 2006-10-05 Endocyte, Inc. Method for cancer prognosis using cellular folate vitamin receptor quantification
JP5175723B2 (en) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション Preparation of compositions for treating monocyte-mediated diseases
EP2382995A3 (en) 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
JP5475992B2 (en) * 2005-08-19 2014-04-16 エンドサイト，インコーポレイテッド Multidrug ligand conjugate
PE20080102A1 (en) 2006-05-25 2008-02-11 Bristol Myers Squibb Co AZIRIDINYL-EPOTILONE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
AU2008224988A1 (en) * 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337339A (en) * 1979-04-30 1982-06-29 Baker Instruments Corp. Process for preparation of folic acid derivatives
US20030162234A1 (en) * 2002-02-07 2003-08-28 Jallad Karim N. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
M.C. ARCHER, L.S. REED: "Separation of Folic Acid Derivatives and Pterins by High-Performance Liquid Chromatography", METHODS IN ENZYMOLOGY, vol. 66, 1980, pages 452 - 459, XP009070564 *
MAKOTO N ET AL: "Development of an efficient intermediate, alpha-[2-(trimethylsilyl)et hoxycarbonyl]folic acid, for the synthesis of folate (gamma)-conjugates, and its application to the synthesis of folate-nucleoside conjugates", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 65, no. 16, 11 August 2000 (2000-08-11), pages 5016 - 5021, XP002314929, ISSN: 0022-3263 *
PJ HARVISON, TI KALMAN: "Synthesis and Biological Activity of Novel Folic Acid Analogues: Pteroyl S-alkylhomocysteine Sulfoximines", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, 1992, XP002393707 *
SCOTT, JOHN M.: "Preparation and purification of pteroic acid from pteroylglutamic acid (folic acid)", METHODS IN ENZYMOLOGY , 66(VITAM. COENZYMES, PT. E), 657-60 CODEN: MENZAU; ISSN: 0076-6879, 1980, XP009070566 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916167B2 (en) 2001-05-02 2014-12-23 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8858914B2 (en) 2002-02-07 2014-10-14 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8865128B2 (en) 2002-02-07 2014-10-21 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8808998B2 (en) 2003-05-30 2014-08-19 Purdue Research Foundation Diagnostic method for atherosclerosis
US9550734B2 (en) 2004-07-23 2017-01-24 Endocyte, Inc. Bivalent linkers and conjugates thereof
US8685752B2 (en) 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
US9180215B2 (en) 2007-02-07 2015-11-10 Purdue Research Foundation Positron emission tomography imaging method
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US8961926B2 (en) 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof

Also Published As

Publication number Publication date
JP5289935B2 (en) 2013-09-11
WO2006101845A2 (en) 2006-09-28
EP1863816A2 (en) 2007-12-12
US8044200B2 (en) 2011-10-25
CN101175757B (en) 2012-11-14
CN101175757A (en) 2008-05-07
EP1863816B1 (en) 2014-06-25
JP2008538743A (en) 2008-11-06
US20080207625A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2006101845A3 (en) Synthesis and purification of pteroic acid and conjugates thereof
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
WO2008009415A3 (en) 4-heteroaryl-substituted 1-aminocyclohexane-1- and cyclohexene-1-derivatives having effects on the opiod receptor system
WO2008017029A3 (en) Drug carriers, their synthesis, and methods of use thereof
WO2006021379A8 (en) Dihydropteridinone derivatives, methods for the production thereof and their use as medicaments
WO2006021378A8 (en) Dihydropteridinone derivatives, methods for the production thereof and their use as medicaments
TW200728307A (en) Novel spirochromanone derivatives
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007016635A3 (en) Process for the purification of coenzyme q10
WO2007150025A3 (en) Purinone derivatives as hm74a agonists
WO2008134048A3 (en) Methods for synthesizing and purifying aminoalkyl tetracycline compounds
WO2007044950A3 (en) Crystalline forms of docetaxel and processes for their preparation
WO2006018184A3 (en) Spirocyclic cyclohexane derivatives
WO2008017491A8 (en) Ligustilide derivatives for the treatment of disorders of the central nervous system
WO2009000552A3 (en) Compositions for the treatment of hyperphenylalaninemia
TW200700062A (en) Pharmaceutical compositions
WO2007047671A3 (en) Tetrahydroquinolines, synthesis thereof, and intermediates thereto
WO2007016029A3 (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
WO2008021346A3 (en) Pure paliperidone and processes for preparing thereof
MX2007006018A (en) Novel oral pharmaceutical suspension of cefdinir crystal.
WO2007002722A3 (en) Synthesis of anastrozole and purification of one of its intermediate
WO2007115929A8 (en) Thiazolyl-dihydroquinazolines
WO2007144699A3 (en) Process for the preparation of alfuzosin
WO2007143152A3 (en) Preparation of (s)-pregabalin-nitrile
WO2007000655A3 (en) Novel pyrazolopyrimidinone derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680016287.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008501969

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11908695

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006738235

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3860/KOLNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU